Brufen
ApprovedSmall molecule
Boehringer IngelheimBrufen is one of 46 small molecule programs targeting Low back pain. It is currently in Approved.
1
Indications
4
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
237 competitors in Low Back Pain
#DrugCompanyPhaseTrials
1Sympazan
LundbeckPhase 3
Tofranil
SanofiPhase 3
Arcoxia
NovartisPhase 3
Suboxone
IIndivior Inc.
Phase 3
Pred Forte
NovartisPhase 3
Keterol
PPamukkale University
Phase 3
Tylenol
KKenvue Brands
Phase 3
Anjeso
Boehringer IngelheimPhase 3
Tanezumab
PfizerPhase 3
Xylocaine
MMEDRx USA, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Post Operative Pain1 trial
Role of Alprazolam in Management of Post Endodontic Pain After Single Visit Root Canal Treatment. To Compare Mean Pain Score Between Two Group of Participants Undergoing Post Operative Pain Management After Single Visit Root Canal Treatment: NSAIDs Alone and a Combination of NSAIDs and Alprazolam.
Not yet recruiting·AArmed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi·N/A·NCT07275710·110 enrolled
Ibuprofen1 trial
Premedication1 trial
Effectiveness of Buccal Infiltration During Vital Pulpotomy After Administering Two Analgesic Premedications
Completed·—·N/A·NCT03423329·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Brufen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company